1 0
Cart
    Inquiry
    Popular Searches: Recombinant Antibody MHC Tetramer T cell Receptor Scaffold Protein
    + Filter
    Loading...
    Custom Services order now ship next day

    CTLA4

    Loading...

    Anti-CTLA4 Products

    More Infomation

    Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag

    More Infomation

    Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us

    For Research Use Only. Not For Clinical Use.


    Creative Biolabs provides a broad selection of high-quality recombinant antibodies targeting CTLA4, tailored to meet the needs of biomedical researchers and institutions. These antibodies are crafted for maximum specificity and reliability across various applications. Our commitment to advancing scientific research is reflected in the innovative solutions we offer, enabling researchers to drive progress in immunology and cancer studies. By utilizing our CTLA4 antibodies, you can elevate your research and contribute to deeper insights into immune regulation.

    CTLA4: A Key Immune Checkpoint of Immune-Related Disease

    CTLA4 (cytotoxic T-lymphocyte-associated protein 4) is a crucial immune checkpoint protein involved in regulating immune responses. It is a transmembrane protein consisting of an extracellular domain, a transmembrane domain, and an intracellular domain. The extracellular domain binds to ligands, while the intracellular domain interacts with signaling molecules to modulate T cell activation. Research on CTLA4 is pivotal for understanding immune regulation and tolerance. Blocking CTLA4 has proven effective in cancer immunotherapy by preventing its inhibitory effect and boosting the anti-tumor immune response. Additionally, a deeper understanding of CTLA4's structure and function can aid in developing innovative therapies for a range of immune-related diseases.

    Alternative Names

    Cytotoxic T-lymphocyte associated protein 4; CD; GSE; GRD4; ALPS5; CD152; CTLA-4; IDDM12; CELIAC3

    Background

    This gene is a member of the immunoglobulin superfamily and encodes a protein that transmits an inhibitory signal to T cells. The protein contains a V domain, a transmembrane domain, and a cytoplasmic tail. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. The membrane-bound isoform functions as a homodimer interconnected by a disulfide bond, while the soluble isoform functions as a monomer. Mutations in this gene have been associated with insulin-dependent diabetes mellitus, Graves disease, Hashimoto thyroiditis, celiac disease, systemic lupus erythematosus, thyroid-associated orbitopathy, and other autoimmune diseases.

    Anti-CTLA4 rAb Products

    Our company offers high-quality anti-CTLA4 recombinant antibodies, supporting research and the development of therapies targeting this important molecule.

    Cat. No. Product Name Target Species Host Species Applications
    TAB-067 Anti-Human CTLA4 Recombinant Antibody (Ipilimumab) Human Human WB; FuncS; IF; Neut; ELISA; FC; IP
    TAB-195CL Mouse Anti-CTLA4 Recombinant Antibody Human Mouse ELISA
    TAB-206 Anti-Human CTLA4 Recombinant Antibody (Ticilimumab (Tremelimumab)) Human Human WB; IF; IP; Neut; FuncS; ELISA; FC
    HPAB-N0054-YC Human Anti-CTLA4 Recombinant Antibody (clone 4H9-G5-D5-B1) Human Chimeric (mouse/human) ELISA; FC
    HPAB-1098-FY Human Anti-CTLA4 Recombinant Antibody Human Human ELISA

    Creative Quality Control

    To meet our customers' expectations for antibody quality, we have implemented a rigorous quality management system. This approach guarantees the excellence of our products, allowing researchers to conduct their work with greater efficiency and ease.

    Fig.1 SDS-PAGE analysis of TAB-206. (Creative Biolabs Original)Fig.1 SDS-PAGE analysis of anti-CTLA4 antibody
    (Cat# TAB-206, Creative Biolabs).

    Fig.2 SEC-HPLC analysis of TAB-206. (Creative Biolabs Original)Fig.2 SEC-HPLC analysis of anti-CTLA4 antibody
    (Cat# TAB-206, Creative Biolabs).

    Fig.3 ELISA analysis of TAB-067. (Creative Biolabs Original)Fig.3 ELISA analysis of anti-CTLA4 antibody
    (Cat# TAB-067, Creative Biolabs).

    Fig.4 WB analysis of TAB-067. (Creative Biolabs Original)Fig.4 WB analysis of anti-CTLA4 antibody
    (Cat# TAB-067, Creative Biolabs).

    Customer Reviews

    Excellent
    L**en
    Anti-Human CTLA4 Recombinant Antibody (Ipilimumab) (Cat#: TAB-067)
    For my research, I utilized the anti-human CTLA4 recombinant antibody to investigate CTLA4 expression in tumor tissues. The antibody yielded outstanding results in both WB and IF assays, delivering precise and distinct signals, which greatly contributed to the accuracy of my study.
    18/Dec/2021
    Excellent
    D**e
    Anti-Human CTLA4 Recombinant Antibody (Ticilimumab (Tremelimumab)) (Cat#: TAB-206)
    The anti-human CTLA4 recombinant antibody played a crucial role in my research. I utilized it across various experiments, including immunofluorescence, immunoprecipitation, and ELISA. It provided precise and consistent results when detecting specific cells or tissues, making it an indispensable tool that significantly advanced my studies.
    9/Oct/2021
    Excellent
    C**al
    Mouse Anti-CTLA4 Recombinant Antibody (Cat#: TAB-195CL)
    As a researcher, I incorporated the mouse anti-CTLA4 recombinant antibody into my experiments, specifically employing it in an ELISA assay to detect CTLA4 expression in immune cells. The results were exceptional. This antibody showed impressive specificity and sensitivity, providing accurate and reliable data for my research. It has proven to be an invaluable tool in my work.
    15/Jul/2022

    rAb Production

    With years of expertise in process optimization, including the development of expression vectors, screening of transfected cell lines, and antibody purification, we are committed to offering comprehensive services to biomedical researchers. From gene synthesis to the final production of high-quality antibodies, we strive to support your research with excellence at every step.

    Featured Anti-CTLA4 Recombinant Antibody Production PlatformsFig.5 Milligram-scale anti-CTLA4 recombinant antibody production. (Creative Biolabs Original)
    Fig.5 Milligram-scale recombinant antibody production.

    Fig.6 Gram-scale anti-CTLA4 recombinant antibody production. (Creative Biolabs Original)Fig.6 Gram-scale recombinant antibody production

    rAb Modalities

    We are fully dedicated to delivering premium recombinant antibodies in multiple formats to researchers. Our goal is to address the varied needs of our clients and equip them with the crucial tools required to advance their research projects.

    Fig.7 Full Length Anti-CTLA4 Recombinant Antibody Production and Modalities. (Creative Biolabs Original) Fig.7 Full Length Anti-CTLA4 Recombinant Antibody Production and Modalities

    Drug Information Targeting CTLA4

    Table 1. Therapeutic approaches targeting CTLA4 in clinical development.

    Research phase Company Classification Indications Details
    Launched - 2022 Akeso Biopharma Biologics Cancer This is a bispecific antibody against PD-1 and CTLA-4 developed by Akeso Biopharma, first-time approved in China in 2022 for the treatment of relapsed/metastatic cervical cancer.
    Launched - 2022 Amgen Biologics Cancer It is an anti-CTLA-4 antibody developed at AstraZeneca first approved and launched in 2022 in the U.S. for the treatment of adult patients with unresectable hepatocellular carcinoma (HCC) followed by durvalumab.
    Launched - 2011 Bristol-Myers Squibb Biologics Acute myeloid leukemia;
    Cancer     		It is a fully human antibody targeting the CTLA-4 receptor, is available in the U.S. and the E.U. for the treatment of unresectable or metastatic melanoma in patients 12 years and older.
    Launched - 2006 Bristol-Myers Squibb Biologics Alopecia This is the first selective modulator of a co-stimulatory signal required for full T-cell activation, was launched in the U.S. by Bristol-Myers Squibb in an intravenous formulation for the treatment of rheumatoid arthritis (RA). E.U. approval and launch took place in 2007.
    Phase III Biocad Combinations Melanoma It is a fixed-dose combination (FDC) of the anti-CTLA-4 monoclonal antibody nurulimab and the anti-PD-1 monoclonal antibody prolgolimab being developed by Biocad as an intravenous immunotherapeutic treatment for melanoma.
    Phase III Innovent Biologics Biologics Acral lentiginous melanoma It is a non-innovator form of the anti-CTLA4 antibody Yervoy[R] (ipilimumab), is in phase III clinical development.
    Phase III Alphamab (Jiangsu) Biopharmaceuticals Biologics Cancer This is a bispecific antibody targeting PD-L1 and CTLA-4 in phase III clinical trials at Jiangsu Alphamab Biopharmaceuticals for the treatment of advanced squamous non-small cell lung cancer (NSCLC).
    Phase III AstraZeneca Biologics Cancer It is a bispecific humanized monoclonal IgG1 antibody targeting programmed cell death 1 (PD-1) and cytotoxic T-lymphocyte associated protein 4 (CTLA-4) developed by MedImmune and its parent company AstraZeneca.
    Phase III BioNTech Biologics Cancer It is a humanized monoclonal antibody targeting CTLA-4 in phase III clinical development at OncoC4 and BioNTech for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose disease progressed on anti-PD-1/PD-L1 antibody-based therapy.
    Phase II/III Agenus Biologics Cancer It is an Fc-engineered human monoclonal antibody against CTLA-4 being developed by Agenus as an intravenous immunotherapeutic for oncological indications.
    Phase II Biokin Pharmaceutical Biologics Cancer This is a bispecific antibody against PD-1 and CTLA4 in phase II clinical development at Biokin Pharmaceutical as an anticancer immunotherapeutic.
    Phase II Akeso Biopharma Biologics Cancer It is a humanized monoclonal antibody targeting CTLA-4 being developed by Merck & Co. as an agent to be used in combination with pembrolizumab for the potential treatment of advanced solid tumors.
    Phase II Xencor Biologics Cancer It is a bispecific monoclonal antibody targeting programmed cell death 1 (PD-1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4) in phase II clinical development at Xencor for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and advanced gynecologic and genitourinary malignancies.
    Phase II Agenus Biologics Cancer This is a human monoclonal antibody directed against CTLA-4.
    Phase I/II Adagene Biologics Cancer It is an anti-CTLA-4 fully human monoclonal antibody in early clinical development at Adagene for the intravenous treatment of advanced solid tumors, including hepatocellular carcinoma (HCC) and metastatic microsatellite-stable (MSS) colorectal cancer (CRC). The candidate is being evaluated in combination with other agents.
    Phase I Alpine Immune Sciences Biologics Cancer It is a PD-L1/CTLA-4 antagonist and PD-L1-dependent CD28 T cell costimulatory, is in early clinical development at AIS Operating (formerly, Alpine Immune Sciences) for the treatment of patients with advanced solid tumors or lymphomas that are refractory or resistant to standard therapy, as single agent and in combination with pembrolizumab.
    Phase I MacroGenics Biologics Cancer This is a bispecific tetravalent dual-affinity re-targeting (DART) diabody that targets PD-1 and CTLA-4. The candidate is in early clinical development at MacroGenics for the treatment of patients with unresectable, locally advanced or metastatic solid tumors.
    Phase I Biocad Biologics Melanoma It is a human monoclonal antibody against CTLA-4 that was developed by Biocad as an immunotherapeutic for the treatment of unresectable/metastatic melanoma. It underwent phase I clinical evaluation as a first-line single-agent treatment for unresectable/metastatic melanoma.
    Phase I Xencor Biologics Cancer It is a bispecific antibody that targets immune checkpoint receptors CTLA-4 and LAG-3, is in early clinical development at Xencor for the treatment of solid tumors.

    If you would like more information about our anti-CTLA4 recombinant antibody products, please don't hesitate to reach out to us at any time. Our team is here to provide assistance and address any inquiries you may have, and we eagerly anticipate the opportunity to establish a mutually beneficial partnership with you.

    Related Diseases
    Rheumatoid Arthritis Rheumatoid Arthritis
    Go to compare

    Go to compare